A comparison of concurrent chemoradiotherapy and radiotherapy in Chinese patients with locally advanced cervical carcinoma: a multi-center study by unknown
Li et al. Radiation Oncology 2014, 9:212
http://www.ro-journal.com/content/9/1/212RESEARCH Open AccessA comparison of concurrent chemoradiotherapy
and radiotherapy in Chinese patients with locally
advanced cervical carcinoma: a multi-center study
Zhijie Li, Shuyan Yang, Lei Liu and Shiyu Han*Abstract
Background: We investigated the efficacy of concurrent chemoradiotherapy (CCRT) over radiotherapy (RT) in
Chinese patients with locally advanced cervical carcinoma.
Patients and methods: Between January 2005 and January 2008, 192 patients with squamous cell carcinoma of the
cervix were included in the study: 96 in arm A (CCRT with 20 mg/m2 cisplatin for 5 days) and 96 in arm B (RT). The
overall response rate was the primary endpoint. The secondary endpoints included overall survival, progression-free
survival, and toxicity.
Results: The 5-year overall response rate was 67% and 53% for the CCRT and RT arms, respectively, and the difference
was statistically significant, while the median overall survival was 68 months (range 3-85 months) and 61 months (range
4-83 months), respectively (P = 0.009). In addition, the median progression-free survival for CCRT was 62 months (range
3-83 months), whereas it was 51 months (range 4-81 months) for the RT arm (P = 0.025). The toxicity profile, both acute
and late, was comparable in both arms.
Conclusion: In summary, we demonstrate that CCRT was effective and better tolerated than RT alone in Chinese
patients with locally advanced cervical carcinoma.
Trial registration: Chinese Clinical Trials Register: ChiCTR-TRC-13003979.
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Cervical carcinoma is an important cause of cancer-related
death in women in developing countries, and thus, con-
tinues to pose a major threat to their health [1,2]. It is the
commonest malignancy among women in China and is
widely prevalent all over the country. The 5-year overall
survival rate mainly depends on the stage of the tumor
[3,4]. It varies from 98% in early stage disease to 10% in
the most advanced stages [5]. In the last decade, survival
has improved due to the development of new treatment
strategies such as the combination of chemotherapy and
radiation [6,7].
Currently, a number of treatment options for patients
with cervical carcinoma are available, including surgery* Correspondence: hanshiyu0451@163.com
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unless otherwise stated.[8,9]; radiotherapy [10,11]; chemotherapy such as car-
boplatin [12], cisplatin [13], paclitaxel [14], topotecan
[15], gemcitabine [16], docetaxel [17], ifosfamide [18],
5-fluorouracil (5-FU) [19], irinotecan [20], mitomycin
[21], and bevacizumab [22]; and hyperthermia [23], either
as a single or combined modality [24,25], wherein the
choice of treatment aims at achieving the best results with
the least morbidity.
Until 1999, the primary treatment for locally advanced
cervical carcinoma was radiotherapy, where the tolerance
of normal tissues limits the dose intensity [5,26]. Recently,
the results of a number of clinical trials have shown that
concurrent chemoradiotherapy (CCRT) provides higher
cure rates than radiotherapy alone [27-29]. Therefore,
CCRT is now considered standard treatment for patients
with tumors in stage IIB or higher [30,31]. However, there
is inadequate data about the efficacy and safety of
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study was to prove the superiority of CCRT over radio-
therapy (RT) alone in terms of survival, failure rate, and
toxicity.
Patients and methods
Between January 2005 and January 2008, 192 patients
with a pathological diagnosis of stage IIB-IIIB squamous
cell carcinoma of the cervix as per the International
Federation of Gynecology and Obstetrics (FIGO) cri-
teria, were recruited to participate in this study. To be
eligible, patients had to be between the ages of 20 and
65 years, with a Karnofsky performance status ≥70,
hemoglobin ≥10 g/dL, leukocyte count ≥3000/mm3, abso-
lute neutrophil count ≥1500/mm3, platelets ≥100,000/mm3,
creatinine clearance ≥50 mL/min, and normal liver function
test results. In addition, informed consent documents were
signed by the patients. Patients with nonsquamous hist-
ology, para-aortic lymph nodes, distant metastases, or syn-
chronous/metachronous malignancy were excluded. The
study was approved by the institutional ethics committees
of Third Affiliated Hospital and the Fourth Affiliated
Hospital of Harbin Medical University with permission
number (KY2005-01 and RR2004-12).
The randomization code was generated using a comput-
erized number generator through the stratified block
randomization method of the SAS package (SAS Institute
Inc., Cary, North Carolina, USA) by a statistician with no
clinical involvement in this trial. After qualifying, patients
were assigned to 2 treatment arms: CCRT (arm A) or RT
(arm B) by investigators at each center. The allocation was
concealed in sequentially numbered, opaque, sealed
envelopes containing the randomization assignments.
In addition, all the outcome assessors and data analysts
were blinded in this study.Figure 1 Flow of participants through trial.The plan was to conduct the research in the Third
Affiliated Hospital and the Fourth Affiliated Hospital
of Harbin Medical University. In preparing for this re-
search, we identified that these 2 centers had offered
CCRT or RT treatment to 192 patients between January
2005 and January 2008. The individuals who were ac-
cepted for CCRT and RT were informed about the re-
search and given an information sheet and signed
informed consent. After the clinical assessment, pa-
tients were randomized to receive CCRT or RT, which
was delivered by fully qualified therapists.
The treatment schedule consisted of external-beam
RT to the pelvic region delivered with 15-MV X-rays.
Pelvic radiation was given in daily fractions of 2 Gy for 5
days/week with a four-field technique (anterior and pos-
terior portals: 0.6 Gy, lateral portals: 0.4 Gy), up to a
total dose of 46 Gy/23 fractions. The upper border of
the pelvic portal was at the L4-L5 junction. The lower
border was at the lowest part of the obturator foramen,
which was modified according to the vaginal extent of the
disease. The lateral borders were kept 1.5-2 cm lateral to
the bony pelvis. When the four-field box technique was
used, the anterior or posterior borders of the lateral por-
tals were kept at the cortex of the pubic symphysis and in
the middle of the S2 vertebrae, respectively, and verified
with a computed tomography (CT) scan with markers and
extended posteriorly, if needed.
A cervical boost was given using the X-ray arch tech-
nique or high-dose-rate (HDR) intracavitary brachyther-
apy at a total dose of 10 Gy. Brachytherapy was conducted
using an iridium-192 source and consisted of 2 separate
endocavitary insertions, with an interval of at least 48 h,
with the help of Fletcher-Suit after-loading applicators
(Radium Chemical Company, New York, USA) and vaginal
cylinders. As per the recommendations of the International
Table 2 Summary of adverse events
Adverse events CCR (n = 96) RT (n = 96)
G3/4 (≥G3) (%) G3/4 (≥G3) (%)
Leukopenia 8/3 (11%) 4/3 (7%)
Thrombocytopenia 2/0 (2%) 0/0 (0%)
Nausea 4/1 (5%) 2/0 (2%)
Diarrhea 11/0 (11%) 4/0 (4%)
Anaemia 3/0 (3%) 1/0 (1%)
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38), orthogonal films (at 45° and 315°) were taken to verify
the placement of the applicators, to evaluate doses, and to
deliver the dosimetric plan. Acceptable doses for the blad-
der and rectum were equivalent to 75% and 70%, respect-
ively, of the dose received at point A on the radiographs;
manual and graphic optimization was allowed.
In addition to RT, patients in the CCRT arm also re-
ceived 20 mg/m2 cisplatin for 5 days, at 21-day intervals
for a total of five cycles.
All measurable lesions were evaluated for tumor re-
sponse according to the Response Evaluation Criteria
in Solid Tumors (RECIST 1.0) [32]. All radiological
assessments were confirmed by extratumoral reviews.
Toxicity was graded according to the National Cancer
Institute Common Toxicity Criteria for Adverse Events
(AEs) (CTCAE) version 3.0 [33].
An intention to treat analysis was performed. Sample
size was calculated with an expected 15% difference
between the 2 arms. Overall survival was calculated
from the day of randomization to the day of death.
Data on patients who were alive were censored on the
date on which they were last known to be alive.
Relapse-free survival was computed from the date of
randomization to the date of relapse, death or completion
of follow-up, whichever occurred first. Data on patients
who were alive and relapse-free were censored at the time
of the last follow-up visit. Overall survival and relapse-free
survival rates were calculated by the Kaplan–Meier
method and a P ≤ 0.05 was considered statistically signifi-
cant. All P values were obtained from 2-tailed t-tests.
Results
In this study, 268 participants were initially screened. Of
these 268 patients, 76 subjects were excluded. Of these 76
patients, 67 did not meet study criteria, and 9 declined toTable 1 Baseline characteristics of participants at trial entry:
Variable










Deaths due to cervical carcinoma (n)
Note: ITT, intent-to-treat; CCR, concurrent chemoradiation; RT, over radiotherapy; yr
and Obstetrics.participate. The remaining 192 patients (CCRT, n = 96;
RT, n = 96) were entered into the study. 173 participants
completed the efficacy assessment. 19 patients withdrew
from the study. The major reasons for withdrawal
were AEs, withdrawn consent, and failure to follow-up
(Figure 1). The baseline characteristics of the patients
were similar in the 2 treatment arms (Table 1).
The median number of treatment cycles was three
(range 1-5) for CCRT, the duration of which was 11
weeks; and three (range 1-5) for RT, the duration of
which was 10 weeks. The main reasons for discontinuation
of treatment were AEs [CCRT versus RT, 6/96 (6.2%) versus
4/96 (4.2%)], consent withdrawal [3/96 (3.1%) versus 2/96
(2.1%)], failure to follow-up [1/96 (1.0%) versus 1/96
(1.0%)], and other reasons [1/96 (1.0%) versus 1/96
(1.0%)].
The overall response rate as determined by the
RECIST criteria, was 67% for CCRT (n = 96) and 53% for
RT (n = 96). The difference was statistically significant
(P < 0.05; Table 2). The median overall survival was 68
months (range 3-85 months) and 61 months (range 4-83
months) for the CCRT and RT arms (P = 0.009), respect-
ively (Figure 2). In addition, the median progression-free
survival was 62 months and 51 months for the CCRT
(range 3-83 months) and RT arms (range 4-81 months),
respectively (P = 0.025; Figure 3).ITT population
CCR (n = 96) RT (n = 96) P value
46.5 (14.1) 46.2 (13.9) 0.9
96 (100.0%) 96 (100.0%) 1.0
39 (40.6%) 41 (42.7%) 0.8
32 (33.3%) 31 (32.3%) 0.9
25 (26.0%) 24 (25.0%) 0.9
4.1 (2.3-6.4) 4.0 (2.2-6.3) 0.9
4.5 (1.9) 4.4 (1.8) 0.7
24 (25.0%) 33 (34.4%) 0.2
s, years; SD, standard deviation; FIGO, International Federation of Gynecology
Figure 2 Overall survival.
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96 CCRT and 96 RT patients were included. The inci-
dence of major hematological toxicities was higher
with CCRT than with RT. Grade 3 or 4 leukopenia was
observed in 11/96 (11%) of patients treated with CCRT
versus 7/96 (7%) of patients treated with RT, while the
corresponding incidences of thrombocytopenia were 2/
96 (2%) versus 0/96 (0%), respectively. The most common
grade 3 or 4 non-hematological toxicities were diarrhea
(CCRT versus RT, 11/96(11%) versus 4/96 (4%)), nausea
((5/96) 5% versus 2/96 (2%)), and anorexia (3/96 (3%) ver-
sus 1/96 (1%)). There were no treatment-related deaths in
either arm.Figure 3 Progression-free survival.Discussion
Radiotherapy has been used as the only therapeutic option
for patients with locally advanced cervical cancer in the
past [34]. As 20-50% of patients with stage IIB and 50-
75% with stage III tumors suffered a relapse, additional
treatments [32], including chemotherapy [12-22] and
hyperthermia [23] were incorporated in order to enhance
the effects of radiotherapy. For example, cisplatin-based
chemotherapy with concurrent radiotherapy has now
taken center stage in the therapy of locally advanced
uterine carcinoma [35].
A previous study from the Gynecological Oncology
Group compared patients who underwent radiotherapy
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The study included participants with stage IIB-IVA cer-
vical carcinoma. The group treated with both radiotherapy
and cisplatin had a higher rate (60%) of 5-year survival
in contrast to the group with hydroxyurea (34%). The
difference in survival was maintained after 10 years (53
and 34%, respectively; P < 0.01). In addition, patients
with highly unfavorable pretreatment prognostic factors
were closely monitored, especially those undergoing the
3-weekly regimen. The 3.5-year survival rate was com-
parable to previous results.
In this study, CCRT also had a favorable safety profile.
The overall frequency of AEs was similar in both arms
and most side effects were not severe. The frequency of
both drug-related AEs and AEs of severe intensity was
higher in the CCRT arm than in the RT arm.
A previous publication concluded that when bulky
disease was defined as tumors larger than 4 cm, tumor
size was also of prognostic importance in FIGO stage II
cervical carcinomas [36]. In this study, there was no signifi-
cant difference in the median and average sizes of tumor
diameter between the 2 groups (P = 0.9 and P = 0.7 respect-
ively), although tumor stages varied from IIB to IIIB.
Tumor size was determined by pathological evaluation in
the CCRTgroup and pretreatment MRI in the RT group.
Our study has several strengths. Firstly, the trial was
randomized thereby reducing selection bias. Secondly,
although there was no consensus regarding the dose
appropriate for CCRT in Chinese patients with locally
advanced cervical carcinoma, this trial suggested that our
treatment was in the therapeutic range. Further studies
with larger sample size and longer duration of CCRT are
needed to further confirm the results of this study.
In conclusion, the results of this study show promising ef-
ficacy and a very acceptable toxicity profile for CCRT in
Chinese patients with locally advanced cervical carcinoma.
The follow-up period is still short, but the encouraging clin-
ical and pathological results warrant further investigation.
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